OpGen, Inc. (OPGN)
NASDAQ: OPGN · IEX Real-Time Price · USD
3.026
-0.004 (-0.13%)
At close: Jul 19, 2024, 4:00 PM
3.010
-0.016 (-0.53%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
OpGen Revenue
OpGen had revenue of $2.67M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $168.15K. In the year 2023, OpGen had annual revenue of $3.42M with 31.11% growth.
Revenue (ttm)
$2.67M
Revenue Growth
-12.39%
P/S Ratio
1.53
Revenue / Employee
$26,730
Employees
100
Market Cap
4.08M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.42M | 811.03K | 31.11% |
Dec 31, 2022 | 2.61M | -1.70M | -39.45% |
Dec 31, 2021 | 4.31M | 91.59K | 2.17% |
Dec 31, 2020 | 4.21M | 715.83K | 20.46% |
Dec 31, 2019 | 3.50M | 552.31K | 18.75% |
Dec 31, 2018 | 2.95M | -264.70K | -8.24% |
Dec 31, 2017 | 3.21M | -814.68K | -20.24% |
Dec 31, 2016 | 4.03M | 867.97K | 27.49% |
Dec 31, 2015 | 3.16M | -968.66K | -23.47% |
Dec 31, 2014 | 4.13M | 1.72M | 71.18% |
Dec 31, 2013 | 2.41M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Regional Health Properties | 17.39M |
iSpecimen | 9.27M |
China Pharma Holdings | 6.42M |
Sintx Technologies | 2.78M |
Akanda | 2.16M |
OPGN News
- 2 months ago - OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q - GlobeNewsWire
- 2 months ago - OpGen Announced 1-for-10 Reverse Stock Split - GlobeNewsWire
- 2 months ago - OpGen Provides Update on Business Operations and Strategic Opportunities - GlobeNewsWire
- 3 months ago - OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K - GlobeNewsWire
- 4 months ago - OpGen Announces Acquisition of Preferred Stock by David Lazar - GlobeNewsWire
- 8 months ago - OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 10 months ago - OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds - GlobeNewsWire
- 1 year ago - OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update - GlobeNewsWire